Evidence map›Paper›PMID 25217841›Full record

ArticleMolecular cancer2014

Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma.

Gang Xu, Fang Yang, Cui-Ling Ding, Lan-Juan Zhao, Hao Ren, Ping Zhao, Wen Wang, Zhong-Tian Qi

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Translational cancer research · 2025
    Article
  8. Chemically modified non-coding RNAs in cancer.Expert reviews in molecular medicine · 2025
    Review
  9. Review
  10. Small nucleolar RNAs: the hidden precursors of cancer ribosomes.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. SnoRNAs: The promising targets for anti-tumor therapy.Journal of pharmaceutical analysis · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gang Xu
Fang Yang
Cui-Ling Ding
Lan-Juan Zhao
Hao Ren
Ping Zhao
Wen WangDepartment of Microbiology, Shanghai Key Laboratory of Medical Biodefense, Second Military Medical University, 800 XiangYin RD, Shanghai 200433, China. wonwin29@126.com.
Zhong-Tian Qi
Second Military Medical University · CNFuzhou General Hospital of Nanjing Military Command · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidence suggests that small nucleolar RNAs (snoRNAs) are involved in tumorigenesis. The roles of small nucleolar RNA 113-1 (SNORD113-1) on the development of hepatocellular carcinoma (HCC) remain unknown.

methodsThe expression of SNORD113-1 was measured in 112 HCC tumor tissues using quantitative RT-PCR and compared with expression levels from with paired non-tumor tissues. The effects of SNORD113-1 on HCC tumorigenesis were investigated in HepG2 and Huh7 cells as well as a xenograft nude mouse model. CpG methylation within the promoter region of the SNORD113-1 gene was identified using Sodium bisulfite sequencing. Cancer pathway reporter investigate the mechanism by which SNORD113-1 suppressed tumorigenesis.

resultsSNORD113-1 expression was significantly downregulated in HCC tumors compared with adjacent non-tumor tissues, and downregulation of SNORD113-1 in HCC tumors was significantly associated with worse survival of patients. In addition, CpG methylation at the promoter region of the SNORD113-1 gene was higher in HCC tumors than adjacent non-tumor tissues. Functionally, SNORD113-1 suppressed cancer cell growth in HepG2 and Huh7 cells and in a xenograft nude mouse model. Furthermore, SNORD113-1 inactivated the phosphorylation of ERK1/2 and SMAD2/3 in MAPK/ERK and TGF-β pathways.

conclusionsSNORD113-1 functions as a tumor suppressor role in HCC and may be important as a potential diagnostic and therapeutic target for HCC.

Indexed as

AdultAnimalsCarcinoma, HepatocellularCell Line, TumorDNA MethylationFemaleGene Expression Regulation, NeoplasticHEK293 CellsHep G2 CellsHumansLiver NeoplasmsMaleMAP Kinase Signaling SystemMiceMice, NudeMiddle AgedRNA, Small Nucleolarsmall nucleolar RNA 113-1, human

Identifiers

PMID25217841
PMCPMC4169825
OpenAlexW2166046244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.